DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Idamycin PFS (Idarubicin Hydrochloride) - Current Clinical Trials

 
 



Idamycin PFS Related Clinical Trials

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome [Recruiting]

A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL) [Recruiting]

Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML [Completed]

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML [Completed]

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia [Recruiting]

Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) [Recruiting]

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction [Completed]

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes [Active, not recruiting]

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) [Active, not recruiting]

Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Terminated]

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Completed]

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Completed]

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) [Completed]

Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia [Recruiting]

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]

Nivolumab in Acute Myeloid Leukemia (AML) [Recruiting]

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes [Completed]

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML [Completed]

4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML) [Recruiting]

Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias [Recruiting]

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Completed]

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes [Active, not recruiting]

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Suspended]

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia [Terminated]

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia [Completed]

Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia [Enrolling by invitation]

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy [Completed]

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia [Completed]

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients [Recruiting]

Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas [Completed]

Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia [Completed]

Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome [Completed]

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia [Completed]

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia [Recruiting]

Phase 1/2 Study of Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) [Active, not recruiting]

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) [Active, not recruiting]

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia [Active, not recruiting]

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) [Not yet recruiting]

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen [Terminated]

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia [Active, not recruiting]

Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML [Recruiting]

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients [Not yet recruiting]

S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia [Recruiting]

Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia [Not yet recruiting]

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia [Recruiting]

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine [Active, not recruiting]

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Completed]

HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia [Recruiting]

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma [Terminated]

Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma [Recruiting]

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma [Completed]

Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients [Recruiting]

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) [Recruiting]

Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos«): Phase I Study [Recruiting]

Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia [Completed]

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia [Completed]

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR [Recruiting]

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia [Completed]

Study Evaluating the Addition of Amifostine (Ethyol´┐Ż) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia [Completed]

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome [Completed]

Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II [Recruiting]

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL [Recruiting]

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia [Completed]

the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient [Recruiting]

A Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML [Recruiting]

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant [Recruiting]

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia [Completed]

Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma [Recruiting]

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia [Completed]

Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 [Completed]

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Active, not recruiting]

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia [Completed]

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) [Withdrawn]

Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) [Completed]

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia [Completed]

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia. [Recruiting]

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) [Completed]

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Completed]

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia [Completed]

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome [Active, not recruiting]

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia [Recruiting]

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia [Recruiting]

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia [Recruiting]

Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia [Recruiting]

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome [Completed]

Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Completed]

Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia [Active, not recruiting]

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed Acute Myeloid Leukemia [Not yet recruiting]

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia [Active, not recruiting]

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) [Completed]

Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) [Completed]

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia [Active, not recruiting]

Adoptive Transfer of Haplo-identical DLI for AML and MDS [Recruiting]

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) [Recruiting]

Alisertib for Acute Myeloid Leukemia [Active, not recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017